By Notice dated March 29, 2001, and published in the Federal Register on April 6, 2001, (66 FR 18305), Ansys Technologies, Inc., 25200 Commercentre Drive, Lake Forest, California 92630, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed below:
| Drug | Schedule |
|---|---|
| Phencyclidine (7471) | II |
| 1-Piperidinocyclohexane- carbonitrile (PCC) (8603) | II |
| Benzoylecgonine (9180) | II |
The firm plans to manufacture the listed controlled substances to produce standards and controls for in-vitro diagnostic drug testing systems.
No comments or objections have been received. DEA has considered the factors in Title 21, United States Code, Section 823(a) and determined that the registration of Ansys Technologies, Inc. to manufacture the listed controlled substances is consistent with the public interest at this time. DEA has investigated Ansys Diagnostics, Inc. on a regular basis to ensure that the company's continued registration is consistent with the public interest. These investigations have included inspection and testing of the company's physical security systems, audits of the company's records, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic classes of controlled substances listed above is granted.
Dated: August 27, 2001.
Laura M. Nagel,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. 01-22454 Filed 9-6-01; 8:45 am]
BILLING CODE 4410-09-M